Association between lipoprotein(a) levels, cumulative lipoprotein(a) burden, and cardiovascular outcomes in patients with acute myocardial infarction: a large-scale cohort study Authors: Zhenwei Wang, Jinying Zhang, Junnan Tang Published: 2025 ABSTRACT AimsTo determine whether lipoprotein(a) [Lp(a)] and cumulative Lp(a) (CumLp(a)) are associated with adverse outcomes in patients with acute myocardial infarction (AMI).MethodsThis cohort study included 2,634 hospitalized patients diagnosed with AMI who underwent coronary angiography at Zhongda Hospital, Southeast University, from July 2013, to December 2021. The main outcome was major adverse cardiac and cerebrovascular events (MACCE), defined as cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, or unplanned revascularization—occurring singly or in combination. We used Cox proportional hazards models, with subgroup and sensitivity analyses, restricted cubic spline (RCS) modeling, and threshold-effect assessment to evaluate the relationships between Lp(a), CumLp(a), and prognosis.ResultsAcross a median 55.2-month follow-up, 907 participants (34.40%) experienced a MACCE, 342 (13.00%) patients had CV death, 177 (6.70%) patients had non-fatal MI, 202 (7.70%) patients had non-fatal stroke, 399 (15.10%) patients underwent unplanned revascularization, and all-cause death occurred in 547 (20.80%) patients. Multivariable Cox regression models demonstrated a significantly increased risk of MACCE, CV death, non-fatal MI, and non-fatal stroke in both the higher Lp(a) and higher CumLp(a) groups compared with the lower groups (HRs for Lp(a): 1.652, 2.157, 3.455, and 1.930; HRs for CumLp(a): 1.697, 1.675, 3.759, and 2.032), and every one-unit rise in CumLp(a), the risk of MACCE, CV death, non-fatal MI and non-fatal stroke increased by 1.3%, 1.4%, 1.9% and 1.2%, respectively. The majority of subgroup and sensitivity checks consistently supported a stable link between Lp(a)/CumLp(a) and the risks of MACCE, CV death, non-fatal MI, and stroke. Analyses using RCS and threshold models revealed that Log10(Lp(a)) had both nonlinear and threshold effects on the risks of MACCE and each single event other than unplanned revascularization, while log10-transformed CumLp(a) showed nonlinear and threshold associations only with MACCE, CV death, and non-fatal MI (nonlinearity P < 0.05).ConclusionsHigher levels of Lp(a) and CumLp(a) are linked to a greater risk of poor outcomes among patients with AMI as the index event, highlighting their potential value for risk stratification and guiding clinical decision-making.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12944-025-02800-6. Introduction According to the Global Burden of Disease 2019, rates of cardiovascular disease (CVD) incidence and mortality have continued to climb in recent years, especially among those with acute myocardial infarction (AMI), making it a significant threat to public health [1, 2]. Although the connection between elevated low-density lipoprotein cholesterol (LDL-C) and the rise in AMI rates and mortality is well recognized—and current clinical recommendations focus on lowering LDL-C to reduce such outcomes—high levels of lipoprotein(a) [Lp(a)] still correlate with an increased likelihood of severe cardiovascular incidents [3, 4]. As a result, Lp(a) is regarded as a possible indicator of persistent cardiovascular vulnerability [5]. Lp(a) was first identified in 1963 by Norwegian geneticist Berg in individuals of Nordic descent. This genetically inherited LDL-like lipoprotein comprises cholesteryl esters, free cholesterol, apolipoprotein(a), apolipoprotein B100, and small quantities of triglycerides and carbohydrates [6, 7]. Although its physiological role is not entirely clear, current evidence has implicated Lp(a) in promoting oxidative stress, inflammation, calcification, thrombosis, and the progression of atherosclerosis in CVD [7–9]. A previous study has shown that approximately 20% of the global population exhibits Lp(a) levels above 500 mg/L, with those exceeding the 90th percentile facing up to a 2.5-fold increase in CVD risk [10]. Evidence from epidemiological and Mendelian randomization studies further supports a consistent link between elevated Lp(a) levels and the risks of CVD, along with cardiovascular mortality [11–15]. Yet, some research indicates no significant relationship between baseline Lp(a) levels and long-term cardiovascular outcomes [16, 17]. A recent large prospective cohort study also identified a strong correlation between cumulative Lp(a) [CumLp(a)] and the 5-year risk of major adverse cardiac and cerebrovascular events (MACCE) in coronary heart disease (CHD) patients across different glycemic states [18]. The findings suggest that Lp(a) may play a part in cardiovascular risk during both primary prevention and the early stages of secondary prevention, while its role in recurrent events under intensive secondary prevention remains unclear. Accordingly, this research aimed to investigate how Lp(a) and CumLp(a) levels relate to adverse outcomes in individuals with AMI as the index event, in the context of existing literature, with the goal of informing better patient risk assessment and management strategies in clinical settings. Methods Study population From July 2013, to December 2021, data were collected at Zhongda Hospital, Southeast University, from individuals who underwent coronary angiography, with the investigation conducted as a single-center retrospective cohort study. Inclusion criteria were: (1) adults (≥ 18 years); (2) a confirmed diagnosis of AMI. Exclusion criteria were: (1) no coronary angiography; (2) prior coronary artery bypass grafting or percutaneous coronary intervention (PCI); (3) previous AMI; (4) non-obstructive AMI; (5) severe infection, hematologic or thyroid disorders, acute liver or kidney dysfunction, or malignancy; (6) in-hospital death; (7) missing Lp(a) or essential clinical data; (8) inability to complete follow-up. Following these criteria, as depicted in Figure S1, a cohort of 2,634 patients with AMI as the index event was established for analysis. The research was conducted in accordance with the Declaration of Helsinki, approved by the Hospital Clinical Research Ethics Committee (2021ZDSYLL152-P01), and written informed consent was obtained from every participant. Clinical data collection and definition The study collected demographic information, including age, sex, and a family history of CHD. Smoking was defined as having smoked regularly in the past, irrespective of current smoking habits, while alcohol consumption was similarly recorded based on past regular use, regardless of present consumption. Anthropometric data encompassed systolic and diastolic blood pressure (SBP and DBP), heart rate, and body mass index (BMI). The study also detailed comorbidities and medication history, covering diabetes, hypertension, hyperlipidemia, stroke, chronic kidney disease (CKD), and the use of antihypertensive, hypoglycemic, and lipid-lowering medications. Diabetes was determined using any of the following: fasting plasma glucose levels ≥ 7.0 mmol/L, random plasma glucose ≥ 11.1 mmol/L, hemoglobin A1c ≥ 6.5%, 2-hour post-load glucose ≥ 11.1 mmol/L during an oral glucose tolerance test, or a documented history of diabetes or the administration of glucose-lowering therapy [19]. A diagnosis of hypertension was made when repeated SBP or DBP readings were ≥ 140/90 mmHg, or when there was evidence of previous hypertension or current treatment with antihypertensive agents [20]. Hyperlipidemia was diagnosed if total cholesterol was ≥ 6.2 mmol/L or triglyceride levels were ≥ 2.3 mmol/L in fasting samples [21]. Stroke encompassed any prior stroke history or a confirmed diagnosis during hospitalization, including ischemic and hemorrhagic types. CKD was defined as either an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 or evidence of persistent renal damage lasting for at least three months [22]. Using the Modification of Diet in Renal Disease (MDRD) formula revised for the Chinese population, the eGFR was calculated [23]. The GRACE score, developed from the Global Registry of Acute Coronary Events and its updated scoring algorithm, was also assessed [24, 25]. Detection and definition of baseline Lp(a) and CumLp(a) Using an immunoturbidimetric assay, baseline Lp(a) in circulation was quantified by allowing the antigen in the sample to bind anti-human Lp(a) antibodies in the reagent, producing an immune complex whose turbidity reflects the concentration present [26]. In our center, Lp(a) levels were measured and reported in mg/L (the standard unit adopted by most clinical laboratories in China; 1 mg/L = 0.1 mg/dL for reference). The established normal reference range for Lp(a) is between 100 and 300 mg/L. Patients were categorized into four quartiles based on baseline Lp(a) levels: Q1 (≤ 120 mg/L), Q2 (121–243 mg/L), Q3 (244–415 mg/L), and Q4 (>415 mg/L). CumLp(a) at baseline was calculated using the formula: CumLp(a) (g/L·years) = Lp(a) (mg/L) × age (years)/1000 [18], leading to the division of patients into quartiles as follows: Q1 (≤ 7.12 g/L·years), Q2 (7.13–15.35 g/L·years), Q3 (15.36–27.32 g/L·years), and Q4 (>27.32 g/L·years). Coronary angiography Two senior cardiologists, unaware of the study protocol, independently reviewed the coronary angiography findings. Any inconsistencies were addressed via discussion or, when needed, by involving a third specialist. The Gensini score, which quantifies coronary artery lesion severity incorporating severity scores, regional multiplication factors, and collateral modulation factors, was employed to evaluate coronary artery disease severity, with detailed scoring methodology available in the literature [27, 28]. Follow-up and clinical outcomes From discharge to death or January 2023, patient follow-up was conducted through clinic appointments, telephone contacts, and review of hospital readmission records. The median follow-up time for MACCE was 42.43 months (interquartile range: 20.10–68.16 months). The primary outcome was MACCE, defined as the occurrence of one or more of the following: cardiovascular death, non-fatal MI, non-fatal stroke, or unplanned revascularization procedures. Secondary outcomes covered each component individually, as well as death from any cause. According to the most recent clinical guidelines [29], all-cause death encompasses deaths resulting from cardiac as well as non-cardiac origins. Deaths of cardiovascular origin include those attributed to MI, heart failure, malignant arrhythmias, or causes not clearly linked to non-cardiac systems. A non-fatal MI is determined by increased cardiac biomarkers in conjunction with typical chest pain or changes observed on an electrocardiogram. Non-fatal stroke, confirmed by a neurologist, involves persistent neurological deficits with corroborative computed tomography or magnetic resonance imaging, including both ischemic and hemorrhagic types. Unplanned revascularization pertains to any corrective procedure on coronary arteries prompted by ischemic symptoms or events, excluding those planned. All endpoints were adjudicated by two cardiologists blind to the study design. To avoid immortal time bias, all key exposure variables—including Lp(a) and CumLp(a)—were measured during the index hospitalization before discharge, and follow-up time was uniformly counted from the date of discharge, ensuring that all participants entered the risk period only after exposure status was definitively established. All endpoints were adjudicated by two cardiologists blinded to the study design, with discrepancies resolved by a third senior cardiologist if necessary, to ensure consistency and accuracy of outcome classification. Statistical analysis In this study, normally distributed continuous variables were presented as mean ± standard deviation, analyzed using independent sample T-test or one-way analysis of variance, while non-normally distributed ones were shown as medians (quartiles) and assessed with Mann-Whitney U or Kruskal-Wallis H tests. Categorical variables were presented in the form of counts and proportions, with group differences assessed by Chi-square tests. Given the non-normal distribution of Lp(a), log10-transformation facilitated its analysis in regression models. Differences in event occurrence across Lp(a) categories were compared using Kaplan-Meier curves and the log-rank test. To evaluate their impact on clinical outcomes, the associations of Lp(a) and CumLp(a) were first explored through univariate Cox regression, after which variables reaching statistical significance, together with age and sex, entered multivariable Cox analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs) calculated. To assess the robustness of these associations, subgroup and sensitivity analyses were carried out. The potential nonlinear effects of Lp(a) and CumLp(a) on endpoint risks were evaluated through restricted cubic spline (RCS) models and threshold effect analysis, with model comparison based on likelihood ratio tests. Statistical analyses were conducted using SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA), R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria), and GraphPad Prism version 8.0 (GraphPad Software Inc., San Diego, CA, USA). A two-sided P-value < 0.05 was considered indicative of statistical significance. Results Baseline profile and outcomes of study population A total of 2,634 participants with AMI as the index event were enrolled in this study (mean age: 63.91 ± 13.00 years; 76.2% male), as shown in Table 1. Among the baseline characteristics, variables that showed significant differences across Lp(a) quartile groups included: age, sex (male), smoking, drinking, diabetes, CKD, proportions of antihypertensive and hypoglycemic drug use, Killip classification, left ventricular ejection fraction, BMI, DBP, heart rate, hemoglobin, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, triglycerides, total cholesterol, LDL-C, apolipoprotein A1, apolipoprotein B, blood urea nitrogen, creatinine, eGFR, fibrinogen, D-dimer, high-sensitivity C-reactive protein, GRACE score, left main disease, left anterior descending artery lesion, left circumflex artery lesion, right coronary artery lesion, three-vessel disease, multivessel disease, number of diseased vessels, Gensini score, complete revascularization, thrombus aspiration, intra-aortic balloon pump, number of stents, total stent length, high-lateral wall STEMI, and discharge use of clopidogrel, ticagrelor, ezetimibe, ivabradine, calcium channel blockers, furosemide, spironolactone, insulin, and oral hypoglycemic drugs (P < 0.05).Table 1Baseline characteristics grouped by quartiles of Lp(a)VariablesTotal populationQ1Q2Q3Q4P valueN2634666654656658Age, years63.91 ± 13.0061.51 ± 13.3262.94 ± 13.1465.77 ± 12.6965.47 ± 12.34< 0.001Male, n (%)2006 (76.20%)538 (80.80%)502 (76.80%)498 (75.90%)468 (71.10%)0.001Smoking, n (%)1416 (53.80%)395 (59.30%)370 (56.60%)348 (53.00%)303 (46.00%)< 0.001Drinking, n (%)912 (34.60%)275 (41.30%)223 (34.10%)230 (35.10%)184 (28.00%)< 0.001Family history of CHD, n (%)295 (11.20%)76 (11.40%)78 (11.90%)74 (11.30%)67 (10.20%)0.785Complications, n (%) Diabetes927 (35.20%)263 (39.50%)198 (30.30%)218 (33.20%)248 (37.70%)0.002 Hypertension1880 (71.40%)483 (72.50%)448 (68.50%)464 (70.70%)485 (73.70%)0.175 Hyperlipidemia1161 (44.20%)318 (47.70%)296 (45.30%)267 (41.10%)280 (42.70%)0.076 Stroke571 (21.70%)136 (20.40%)128 (19.60%)155 (23.60%)152 (23.10%)0.205 CKD486 (18.50%)80 (12.00%)87 (13.30%)146 (22.30%)173 (26.30%)< 0.001Medication history, n (%) Antihypertensive drugs1320 (50.10%)361 (54.20%)304 (46.50%)324 (49.40%)331 (50.30%)0.045 Hypoglycemic drugs606 (23.00%)168 (25.20%)126 (19.30%)141 (21.50%)171 (26.00%)0.011 Lipid-lowering drugs34 (1.30%)9 (1.40%)5 (0.80%)7 (1.10%)13 (2.00%)0.249 STEMI, n (%)1403 (53.30%)327 (49.10%)361 (55.20%)365 (55.60%)350 (53.20%)0.068STEMI ECG localisation, n (%) Anterior wall381 (14.50%)82 (12.30%)105 (16.10%)95 (14.50%)99 (15.00%)0.260 Anteroseptal wall186 (7.10%)40 (6.00%)48 (7.30%)42 (6.40%)56 (8.50%)0.290 Anterolateral wall57 (2.20%)13 (2.00%)15 (2.30%)13 (2.00%)16 (2.40%)0.915 Extensive anterior wall237 (9.00%)62 (9.30%)58 (8.90%)53 (8.10%)64 (9.70%)0.754 Inferior wall642 (24.40%)147 (22.10%)169 (25.80%)178 (27.10%)148 (22.50%)0.084 posterior wall119 (4.50%)32 (4.80%)31 (4.70%)31 (4.70%)25 (3.80%)0.788 High-lateral wall75 (2.80%)9 (1.40%)22 (3.40%)25 (3.80%)19 (2.90%)0.042 Right ventricular90 (3.40%)23 (3.50%)26 (4.00%)25 (3.80%)16 (2.40%)0.413Killip class, n (%)< 0.001 I1899 (72.10%)538 (80.80%)524 (80.10%)459 (70.00%)378 (57.40%) II499 (18.90%)98 (14.70%)97 (14.80%)128 (19.50%)176 (26.70%) III115 (4.40%)14 (2.10%)12 (1.80%)37 (5.60%)52 (7.90%) IV121 (4.60%)16 (2.40%)21 (3.20%)32 (4.90%)52 (7.90%)LVEF, %57.67 ± 12.2958.94 ± 11.7858.97 ± 11.3956.54 ± 12.5956.20 ± 13.07< 0.001BMI, kg/m224.93 ± 3.5525.18 ± 3.3925.12 ± 3.6324.68 ± 3.4124.71 ± 3.760.022SBP, mmHg131.56 ± 21.93131.53 ± 22.19132.10 ± 21.95130.80 ± 21.66131.80 ± 21.930.739DBP, mmHg78.18 ± 14.2079.52 ± 14.3378.20 ± 13.7777.37 ± 14.3477.61 ± 14.260.028Heart rate, beats/min80.29 ± 15.3381.27 ± 15.2578.99 ± 13.8980.13 ± 16.3280.75 ± 15.710.044WBC, x109/L9.80 ± 3.799.87 ± 3.699.83 ± 3.929.94 ± 3.919.55 ± 3.640.264Hemoglobin, g/L137.46 ± 20.76141.65 ± 19.59139.69 ± 20.50136.17 ± 20.53132.27 ± 21.19< 0.001Platelet, x109/L213.00 ± 63.89210.40 ± 62.84207.87 ± 60.87214.38 ± 63.99219.37 ± 67.250.007ALT, U/L31.00 (19.00, 52.00)36.00 (23.50, 56.00)38.00 (23.25, 56.00)25.00 (16.00, 45.00)33.00 (17.50, 57.50)< 0.001AST, U/L53.00 (26.00, 147.00)92.00 (41.00, 192.50)110.50 (31.00, 215.25)42.00 (21.00, 141.50)56.00 (24.00, 136.50)< 0.001Total bilirubin, umol/L14.30 ± 7.8715.33 ± 8.9414.85 ± 8.3913.47 ± 6.7113.55 ± 7.05< 0.001Albumin, g/L38.02 ± 4.3738.99 ± 4.0038.34 ± 4.2237.54 ± 4.3637.19 ± 4.68< 0.001Triglyceride, mmol/L1.46 (1.06, 2.09)1.40 (1.10, 2.02)1.41 (1.05, 1.94)1.36 (1.02, 1.96)1.38 (0.99, 2.11)< 0.001Total cholesterol, mmol/L4.56 ± 1.164.41 ± 1.134.53 ± 1.144.59 ± 1.094.70 ± 1.24< 0.001LDL-C, mmol/L2.80 ± 0.872.58 ± 0.812.79 ± 0.832.88 ± 0.832.95 ± 0.96< 0.001HDL-C, mmol/L1.12 ± 0.261.14 ± 0.261.12 ± 0.261.10 ± 0.261.12 ± 0.250.126ApoA1, g/L1.05 ± 0.241.08 ± 0.241.07 ± 0.241.02 ± 0.251.04 ± 0.24< 0.001ApoB, g/L0.84 ± 0.230.79 ± 0.220.84 ± 0.220.86 ± 0.220.88 ± 0.27< 0.001Lp(a), mg/L243.00 (120.00, 415.25)69.00 (44.00, 95.00)180.50 (148.75, 211.00)318.50 (279.00, 357.00)619.00 (494.00, 833.50)< 0.001Log10(Lp(a))2.33 ± 0.421.77 ± 0.292.25 ± 0.092.50 ± 0.072.82 ± 0.15< 0.001CumLp(a), g/L·years15.35 (7.12, 27.32)4.00 (2.57, 5.66)11.10 (8.83, 13.52)20.60 (17.61, 24.59)40.60 (32.34, 55.75)< 0.001BUN, mmol/L5.50 (4.40, 7.00)5.40 (4.10, 6.95)5.30 (4.30, 6.78)5.80 (4.35, 8.20)6.10 (4.80, 8.60)< 0.001Creatinine, umol/L83.00 (70.00, 100.00)74.00 (62.00, 90.00)77.50 (67.25, 92.00)83.00 (65.00, 106.00)82.00 (68.00, 106.00)< 0.001eGFR, ml/min/1.73m287.59 ± 34.7096.33 ± 34.3490.56 ± 32.8182.62 ± 34.0880.76 ± 35.31< 0.001Uric acid, umol/L358.78 ± 112.64355.09 ± 103.87354.12 ± 106.97359.13 ± 108.12366.81 ± 129.600.159FBG, mmol/L6.16 (5.29, 7.87)6.58 (5.38, 8.24)6.09 (5.33, 7.73)6.17 (5.41, 8.37)6.57 (5.50, 9.00)0.138HbA1c, %6.86 ± 1.776.75 ± 1.686.81 ± 1.786.94 ± 1.816.96 ± 1.830.330Fibrinogen, g/L3.88 ± 0.893.66 ± 0.853.75 ± 0.854.00 ± 0.884.11 ± 0.88< 0.001D-dimer, ug/L152.00 (84.00, 289.00)144.00 (71.50, 293.00)167.50 (78.25, 311.50)177.00 (84.00, 429.00)233.00 (134.00, 518.00)< 0.001Hs-CRP, mg/L8.12 (1.80, 29.20)3.37 (0.88, 20.55)6.31 (0.89, 17.88)6.61 (1.91, 23.89)9.91 (2.09, 42.45)< 0.001GRACE score118.80 ± 31.87109.10 ± 28.91112.24 ± 28.94124.43 ± 31.50129.53 ± 33.45< 0.001Coronary angiography, n (%) Myocardial bridge232 (8.80%)70 (10.50%)67 (10.20%)48 (7.30%)47 (7.10%)0.043 Left main disease249 (9.50%)42 (6.30%)43 (6.60%)76 (11.60%)88 (13.40%)< 0.001 Left anterior descending branch lesion2411 (91.50%)596 (89.50%)585 (89.40%)600 (91.50%)630 (95.70%)< 0.001 Left circumflex branch lesion1819 (69.10%)445 (66.80%)431 (65.90%)460 (70.10%)483 (73.40%)0.013 Right coronary artery lesion1953 (74.10%)474 (71.20%)456 (69.70%)491 (74.80%)532 (80.90%)< 0.001 Three-vessel disease1449 (55.00%)332 (49.80%)325 (49.70%)369 (56.30%)423 (64.30%)< 0.001 Multiple vessel disease2147 (81.50%)521 (78.20%)505 (77.20%)542 (82.60%)579 (88.00%)< 0.001 Number of diseased vessels2.37 ± 0.772.28 ± 0.802.27 ± 0.812.39 ± 0.762.52 ± 0.70< 0.001 Gensini score72.00 (45.75, 102.00)70.00 (44.00, 98.00)73.00 (46.00, 101.50)82.00 (46.00, 103.00)94.00 (56.00, 117.00)< 0.001 Complete revascularization2228 (84.60%)577 (86.60%)571 (87.30%)553 (84.30%)527 (80.10%)0.001 PCI/CABG2298 (87.20%)570 (85.60%)582 (89.00%)564 (86.00%)582 (88.40%)0.155 Thrombus aspiration725 (27.50%)173 (26.00%)203 (31.00%)198 (30.20%)151 (22.90%)0.003 Intra-aortic ballon pump27 (1.00%)4 (0.60%)4 (0.60%)5 (0.80%)14 (2.10%)0.014 Number of stent1.00 (1.00, 2.00)1.00 (1.00, 2.00)1.00 (1.00, 2.00)1.00 (1.00, 2.00)2.00 (1.00, 2.00)0.004 Stent length, mm30.00 (18.00, 52.00)28.00 (18.00, 47.00)33.00 (22.25, 52.75)30.00 (18.00, 52.50)42.00 (23.50, 61.50)0.004 Heparin, u9000.0 (8000.0, 9500.0)9000.0 (8000.0, 10000.0)9000.0 (8000.0, 10000.0)8500.0 (8000.0, 9500.0)9000.0 (8000.0, 10000.0)0.046 Operation time, min60.00 (44.75, 80.00)60.00 (42.50, 78.00)60.00 (45.00, 84.25)60.00 (50.00, 80.50)62.00 (50.00, 85.50)0.226Discharge medication, n (%) Aspirin2496 (94.80%)631 (94.70%)626 (95.70%)617 (94.10%)622 (94.50%)0.585 Clopidogrel1073 (40.70%)242 (36.30%)261 (39.90%)277 (42.20%)293 (44.50%)0.018 Ticagrelor1533 (58.20%)419 (62.90%)390 (59.60%)368 (56.10%)356 (54.10%)0.006 Statin2547 (96.70%)643 (96.50%)628 (96.00%)639 (97.40%)637 (96.80%)0.564 Ezetimibe1070 (40.60%)309 (46.40%)267 (40.80%)237 (36.10%)257 (39.10%)0.002 PCSK9i188 (7.10%)60 (9.00%)48 (7.30%)37 (5.60%)43 (6.50%)0.105 Beta blocker2105 (79.90%)536 (80.50%)525 (80.30%)522 (79.60%)522 (79.30%)0.946 Ivabradine188 (7.10%)71 (10.70%)41 (6.30%)39 (5.90%)37 (5.60%)0.001 ACEI/ARB1553 (59.00%)392 (58.90%)404 (61.80%)379 (57.80%)378 (57.40%)0.370 Calcium channel blocker424 (16.10%)123 (18.50%)90 (13.80%)92 (14.00%)119 (18.10%)0.024 Sacubitril/valsartan sodium212 (8.00%)61 (9.20%)54 (8.30%)47 (7.20%)50 (7.60%)0.568 Furosemide793 (30.10%)164 (24.60%)171 (26.10%)221 (33.70%)237 (36.00%)< 0.001 Spironolactone809 (30.70%)174 (26.10%)173 (26.50%)218 (33.20%)244 (37.10%)< 0.001 Insulin354 (13.40%)96 (14.40%)73 (11.20%)77 (11.70%)108 (16.40%)0.018 Oral hypoglycemic drugs534 (20.30%)160 (24.00%)123 (18.80%)129 (19.70%)122 (18.50%)0.045Clinical outcomes MACCE907 (34.43%)170 (25.50%)149 (22.80%)240 (36.60%)348 (52.90%)< 0.001 Cardiovascular death342 (12.98%)35 (5.30%)40 (6.10%)108 (16.50%)159 (24.20%)< 0.001 Non-fatal MI177 (6.72%)25 (3.80%)27 (4.10%)36 (5.50%)89 (13.50%)< 0.001 Non-fatal stroke202 (7.67%)35 (5.30%)38 (5.80%)52 (7.90%)77 (11.70%)< 0.001 Unplanned revascularization399 (15.15%)107 (16.10%)79 (12.10%)100 (15.20%)113 (17.20%)0.062 All-cause death547 (20.77%)90 (13.50%)97 (14.80%)166 (25.30%)194 (29.50%)< 0.001Lp(a) Lipoprotein(a), CHD Coronary heart disease, CKD Cronic kidney disease, STEMI ST-segment elevation myocardial infarction, LVEF Left ventricular ejection fraction, BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, WBC White blood cell count, ALT Alanine aminotransferase, AST Aspartate aminotransferase, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, ApoA1 Apolipoprotein A1, ApoB Apolipoprotein B, CumLp(a) Cumulative lipoprotein(a), BUN Blood urea nitrogen, eGFR Estimated glomerular filtration rate, FBG Fasting blood glucose, HbA1c Hemoglobin A1c, Hs-CRP High-sensitivity C-reactive protein, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, IABP Intra-aortic balloon pumping, PCSK9i Proprotein convertase subtilisin/kexin type 9 inhibitors, ACEI Angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blockers Table 1Baseline characteristics grouped by quartiles of Lp(a)VariablesTotal populationQ1Q2Q3Q4P valueN2634666654656658Age, years63.91 ± 13.0061.51 ± 13.3262.94 ± 13.1465.77 ± 12.6965.47 ± 12.34< 0.001Male, n (%)2006 (76.20%)538 (80.80%)502 (76.80%)498 (75.90%)468 (71.10%)0.001Smoking, n (%)1416 (53.80%)395 (59.30%)370 (56.60%)348 (53.00%)303 (46.00%)< 0.001Drinking, n (%)912 (34.60%)275 (41.30%)223 (34.10%)230 (35.10%)184 (28.00%)< 0.001Family history of CHD, n (%)295 (11.20%)76 (11.40%)78 (11.90%)74 (11.30%)67 (10.20%)0.785Complications, n (%) Diabetes927 (35.20%)263 (39.50%)198 (30.30%)218 (33.20%)248 (37.70%)0.002 Hypertension1880 (71.40%)483 (72.50%)448 (68.50%)464 (70.70%)485 (73.70%)0.175 Hyperlipidemia1161 (44.20%)318 (47.70%)296 (45.30%)267 (41.10%)280 (42.70%)0.076 Stroke571 (21.70%)136 (20.40%)128 (19.60%)155 (23.60%)152 (23.10%)0.205 CKD486 (18.50%)80 (12.00%)87 (13.30%)146 (22.30%)173 (26.30%)< 0.001Medication history, n (%) Antihypertensive drugs1320 (50.10%)361 (54.20%)304 (46.50%)324 (49.40%)331 (50.30%)0.045 Hypoglycemic drugs606 (23.00%)168 (25.20%)126 (19.30%)141 (21.50%)171 (26.00%)0.011 Lipid-lowering drugs34 (1.30%)9 (1.40%)5 (0.80%)7 (1.10%)13 (2.00%)0.249 STEMI, n (%)1403 (53.30%)327 (49.10%)361 (55.20%)365 (55.60%)350 (53.20%)0.068STEMI ECG localisation, n (%) Anterior wall381 (14.50%)82 (12.30%)105 (16.10%)95 (14.50%)99 (15.00%)0.260 Anteroseptal wall186 (7.10%)40 (6.00%)48 (7.30%)42 (6.40%)56 (8.50%)0.290 Anterolateral wall57 (2.20%)13 (2.00%)15 (2.30%)13 (2.00%)16 (2.40%)0.915 Extensive anterior wall237 (9.00%)62 (9.30%)58 (8.90%)53 (8.10%)64 (9.70%)0.754 Inferior wall642 (24.40%)147 (22.10%)169 (25.80%)178 (27.10%)148 (22.50%)0.084 posterior wall119 (4.50%)32 (4.80%)31 (4.70%)31 (4.70%)25 (3.80%)0.788 High-lateral wall75 (2.80%)9 (1.40%)22 (3.40%)25 (3.80%)19 (2.90%)0.042 Right ventricular90 (3.40%)23 (3.50%)26 (4.00%)25 (3.80%)16 (2.40%)0.413Killip class, n (%)< 0.001 I1899 (72.10%)538 (80.80%)524 (80.10%)459 (70.00%)378 (57.40%) II499 (18.90%)98 (14.70%)97 (14.80%)128 (19.50%)176 (26.70%) III115 (4.40%)14 (2.10%)12 (1.80%)37 (5.60%)52 (7.90%) IV121 (4.60%)16 (2.40%)21 (3.20%)32 (4.90%)52 (7.90%)LVEF, %57.67 ± 12.2958.94 ± 11.7858.97 ± 11.3956.54 ± 12.5956.20 ± 13.07< 0.001BMI, kg/m224.93 ± 3.5525.18 ± 3.3925.12 ± 3.6324.68 ± 3.4124.71 ± 3.760.022SBP, mmHg131.56 ± 21.93131.53 ± 22.19132.10 ± 21.95130.80 ± 21.66131.80 ± 21.930.739DBP, mmHg78.18 ± 14.2079.52 ± 14.3378.20 ± 13.7777.37 ± 14.3477.61 ± 14.260.028Heart rate, beats/min80.29 ± 15.3381.27 ± 15.2578.99 ± 13.8980.13 ± 16.3280.75 ± 15.710.044WBC, x109/L9.80 ± 3.799.87 ± 3.699.83 ± 3.929.94 ± 3.919.55 ± 3.640.264Hemoglobin, g/L137.46 ± 20.76141.65 ± 19.59139.69 ± 20.50136.17 ± 20.53132.27 ± 21.19< 0.001Platelet, x109/L213.00 ± 63.89210.40 ± 62.84207.87 ± 60.87214.38 ± 63.99219.37 ± 67.250.007ALT, U/L31.00 (19.00, 52.00)36.00 (23.50, 56.00)38.00 (23.25, 56.00)25.00 (16.00, 45.00)33.00 (17.50, 57.50)< 0.001AST, U/L53.00 (26.00, 147.00)92.00 (41.00, 192.50)110.50 (31.00, 215.25)42.00 (21.00, 141.50)56.00 (24.00, 136.50)< 0.001Total bilirubin, umol/L14.30 ± 7.8715.33 ± 8.9414.85 ± 8.3913.47 ± 6.7113.55 ± 7.05< 0.001Albumin, g/L38.02 ± 4.3738.99 ± 4.0038.34 ± 4.2237.54 ± 4.3637.19 ± 4.68< 0.001Triglyceride, mmol/L1.46 (1.06, 2.09)1.40 (1.10, 2.02)1.41 (1.05, 1.94)1.36 (1.02, 1.96)1.38 (0.99, 2.11)< 0.001Total cholesterol, mmol/L4.56 ± 1.164.41 ± 1.134.53 ± 1.144.59 ± 1.094.70 ± 1.24< 0.001LDL-C, mmol/L2.80 ± 0.872.58 ± 0.812.79 ± 0.832.88 ± 0.832.95 ± 0.96< 0.001HDL-C, mmol/L1.12 ± 0.261.14 ± 0.261.12 ± 0.261.10 ± 0.261.12 ± 0.250.126ApoA1, g/L1.05 ± 0.241.08 ± 0.241.07 ± 0.241.02 ± 0.251.04 ± 0.24< 0.001ApoB, g/L0.84 ± 0.230.79 ± 0.220.84 ± 0.220.86 ± 0.220.88 ± 0.27< 0.001Lp(a), mg/L243.00 (120.00, 415.25)69.00 (44.00, 95.00)180.50 (148.75, 211.00)318.50 (279.00, 357.00)619.00 (494.00, 833.50)< 0.001Log10(Lp(a))2.33 ± 0.421.77 ± 0.292.25 ± 0.092.50 ± 0.072.82 ± 0.15< 0.001CumLp(a), g/L·years15.35 (7.12, 27.32)4.00 (2.57, 5.66)11.10 (8.83, 13.52)20.60 (17.61, 24.59)40.60 (32.34, 55.75)< 0.001BUN, mmol/L5.50 (4.40, 7.00)5.40 (4.10, 6.95)5.30 (4.30, 6.78)5.80 (4.35, 8.20)6.10 (4.80, 8.60)< 0.001Creatinine, umol/L83.00 (70.00, 100.00)74.00 (62.00, 90.00)77.50 (67.25, 92.00)83.00 (65.00, 106.00)82.00 (68.00, 106.00)< 0.001eGFR, ml/min/1.73m287.59 ± 34.7096.33 ± 34.3490.56 ± 32.8182.62 ± 34.0880.76 ± 35.31< 0.001Uric acid, umol/L358.78 ± 112.64355.09 ± 103.87354.12 ± 106.97359.13 ± 108.12366.81 ± 129.600.159FBG, mmol/L6.16 (5.29, 7.87)6.58 (5.38, 8.24)6.09 (5.33, 7.73)6.17 (5.41, 8.37)6.57 (5.50, 9.00)0.138HbA1c, %6.86 ± 1.776.75 ± 1.686.81 ± 1.786.94 ± 1.816.96 ± 1.830.330Fibrinogen, g/L3.88 ± 0.893.66 ± 0.853.75 ± 0.854.00 ± 0.884.11 ± 0.88< 0.001D-dimer, ug/L152.00 (84.00, 289.00)144.00 (71.50, 293.00)167.50 (78.25, 311.50)177.00 (84.00, 429.00)233.00 (134.00, 518.00)< 0.001Hs-CRP, mg/L8.12 (1.80, 29.20)3.37 (0.88, 20.55)6.31 (0.89, 17.88)6.61 (1.91, 23.89)9.91 (2.09, 42.45)< 0.001GRACE score118.80 ± 31.87109.10 ± 28.91112.24 ± 28.94124.43 ± 31.50129.53 ± 33.45< 0.001Coronary angiography, n (%) Myocardial bridge232 (8.80%)70 (10.50%)67 (10.20%)48 (7.30%)47 (7.10%)0.043 Left main disease249 (9.50%)42 (6.30%)43 (6.60%)76 (11.60%)88 (13.40%)< 0.001 Left anterior descending branch lesion2411 (91.50%)596 (89.50%)585 (89.40%)600 (91.50%)630 (95.70%)< 0.001 Left circumflex branch lesion1819 (69.10%)445 (66.80%)431 (65.90%)460 (70.10%)483 (73.40%)0.013 Right coronary artery lesion1953 (74.10%)474 (71.20%)456 (69.70%)491 (74.80%)532 (80.90%)< 0.001 Three-vessel disease1449 (55.00%)332 (49.80%)325 (49.70%)369 (56.30%)423 (64.30%)< 0.001 Multiple vessel disease2147 (81.50%)521 (78.20%)505 (77.20%)542 (82.60%)579 (88.00%)< 0.001 Number of diseased vessels2.37 ± 0.772.28 ± 0.802.27 ± 0.812.39 ± 0.762.52 ± 0.70< 0.001 Gensini score72.00 (45.75, 102.00)70.00 (44.00, 98.00)73.00 (46.00, 101.50)82.00 (46.00, 103.00)94.00 (56.00, 117.00)< 0.001 Complete revascularization2228 (84.60%)577 (86.60%)571 (87.30%)553 (84.30%)527 (80.10%)0.001 PCI/CABG2298 (87.20%)570 (85.60%)582 (89.00%)564 (86.00%)582 (88.40%)0.155 Thrombus aspiration725 (27.50%)173 (26.00%)203 (31.00%)198 (30.20%)151 (22.90%)0.003 Intra-aortic ballon pump27 (1.00%)4 (0.60%)4 (0.60%)5 (0.80%)14 (2.10%)0.014 Number of stent1.00 (1.00, 2.00)1.00 (1.00, 2.00)1.00 (1.00, 2.00)1.00 (1.00, 2.00)2.00 (1.00, 2.00)0.004 Stent length, mm30.00 (18.00, 52.00)28.00 (18.00, 47.00)33.00 (22.25, 52.75)30.00 (18.00, 52.50)42.00 (23.50, 61.50)0.004 Heparin, u9000.0 (8000.0, 9500.0)9000.0 (8000.0, 10000.0)9000.0 (8000.0, 10000.0)8500.0 (8000.0, 9500.0)9000.0 (8000.0, 10000.0)0.046 Operation time, min60.00 (44.75, 80.00)60.00 (42.50, 78.00)60.00 (45.00, 84.25)60.00 (50.00, 80.50)62.00 (50.00, 85.50)0.226Discharge medication, n (%) Aspirin2496 (94.80%)631 (94.70%)626 (95.70%)617 (94.10%)622 (94.50%)0.585 Clopidogrel1073 (40.70%)242 (36.30%)261 (39.90%)277 (42.20%)293 (44.50%)0.018 Ticagrelor1533 (58.20%)419 (62.90%)390 (59.60%)368 (56.10%)356 (54.10%)0.006 Statin2547 (96.70%)643 (96.50%)628 (96.00%)639 (97.40%)637 (96.80%)0.564 Ezetimibe1070 (40.60%)309 (46.40%)267 (40.80%)237 (36.10%)257 (39.10%)0.002 PCSK9i188 (7.10%)60 (9.00%)48 (7.30%)37 (5.60%)43 (6.50%)0.105 Beta blocker2105 (79.90%)536 (80.50%)525 (80.30%)522 (79.60%)522 (79.30%)0.946 Ivabradine188 (7.10%)71 (10.70%)41 (6.30%)39 (5.90%)37 (5.60%)0.001 ACEI/ARB1553 (59.00%)392 (58.90%)404 (61.80%)379 (57.80%)378 (57.40%)0.370 Calcium channel blocker424 (16.10%)123 (18.50%)90 (13.80%)92 (14.00%)119 (18.10%)0.024 Sacubitril/valsartan sodium212 (8.00%)61 (9.20%)54 (8.30%)47 (7.20%)50 (7.60%)0.568 Furosemide793 (30.10%)164 (24.60%)171 (26.10%)221 (33.70%)237 (36.00%)< 0.001 Spironolactone809 (30.70%)174 (26.10%)173 (26.50%)218 (33.20%)244 (37.10%)< 0.001 Insulin354 (13.40%)96 (14.40%)73 (11.20%)77 (11.70%)108 (16.40%)0.018 Oral hypoglycemic drugs534 (20.30%)160 (24.00%)123 (18.80%)129 (19.70%)122 (18.50%)0.045Clinical outcomes MACCE907 (34.43%)170 (25.50%)149 (22.80%)240 (36.60%)348 (52.90%)< 0.001 Cardiovascular death342 (12.98%)35 (5.30%)40 (6.10%)108 (16.50%)159 (24.20%)< 0.001 Non-fatal MI177 (6.72%)25 (3.80%)27 (4.10%)36 (5.50%)89 (13.50%)< 0.001 Non-fatal stroke202 (7.67%)35 (5.30%)38 (5.80%)52 (7.90%)77 (11.70%)< 0.001 Unplanned revascularization399 (15.15%)107 (16.10%)79 (12.10%)100 (15.20%)113 (17.20%)0.062 All-cause death547 (20.77%)90 (13.50%)97 (14.80%)166 (25.30%)194 (29.50%)< 0.001Lp(a) Lipoprotein(a), CHD Coronary heart disease, CKD Cronic kidney disease, STEMI ST-segment elevation myocardial infarction, LVEF Left ventricular ejection fraction, BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, WBC White blood cell count, ALT Alanine aminotransferase, AST Aspartate aminotransferase, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, ApoA1 Apolipoprotein A1, ApoB Apolipoprotein B, CumLp(a) Cumulative lipoprotein(a), BUN Blood urea nitrogen, eGFR Estimated glomerular filtration rate, FBG Fasting blood glucose, HbA1c Hemoglobin A1c, Hs-CRP High-sensitivity C-reactive protein, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, IABP Intra-aortic balloon pumping, PCSK9i Proprotein convertase subtilisin/kexin type 9 inhibitors, ACEI Angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blockers Baseline characteristics grouped by quartiles of Lp(a) Lp(a) Lipoprotein(a), CHD Coronary heart disease, CKD Cronic kidney disease, STEMI ST-segment elevation myocardial infarction, LVEF Left ventricular ejection fraction, BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, WBC White blood cell count, ALT Alanine aminotransferase, AST Aspartate aminotransferase, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, ApoA1 Apolipoprotein A1, ApoB Apolipoprotein B, CumLp(a) Cumulative lipoprotein(a), BUN Blood urea nitrogen, eGFR Estimated glomerular filtration rate, FBG Fasting blood glucose, HbA1c Hemoglobin A1c, Hs-CRP High-sensitivity C-reactive protein, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, IABP Intra-aortic balloon pumping, PCSK9i Proprotein convertase subtilisin/kexin type 9 inhibitors, ACEI Angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blockers Besides, as shown in Figure S2 and Table 1, during the 55.2-month median follow-up, 34.40% of patients experienced MACCE, 13.00% suffered cardiovascular death, 6.70% had non-fatal MI, 7.70% encountered non-fatal stroke, 15.10% underwent unplanned revascularization, and 20.80% died from all causes. The incidence of MACCE, as well as its individual outcomes other than unplanned revascularization, differed significantly across Lp(a) quartiles, with the highest rates noted in the Q4 group (P < 0.001). As presented in Figs. 1 and 2, Kaplan–Meier analyses demonstrated notable differences in the cumulative incidence of MACCE and its individual outcomes — including cardiovascular death non-fatal MI, non-fatal stroke, and deaths from any cause — across the four Lp(a) and CumLp(a) categories (Log-rank P < 0.001). In contrast, for unplanned revascularization, a significant difference was detected only among the Lp(a) quartiles (Log-rank P = 0.019), whereas no meaningful variation was observed among the CumLp(a) groups (Log-rank P = 0.550).Fig. 1Kaplan-Meier survival curves for Lp(a) in relation to endpoint events. A: Lp(a) and MACCE, B: Lp(a) and CV death, C: Lp(a) and non-fatal MI, D: Lp(a) and non-fatal stroke, E: Lp(a) and unplanned RV, F: Lp(a) and all-cause death.Lp(a), lipoprotein(a); CumLp(a), cumulative lipoprotein(a); MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; RV, revascularizationFig. 2Kaplan-Meier survival curves for CumLp(a) in relation to endpoint events. A: CumLp(a) and MACCE, B: CumLp(a) and CV death, C: CumLp(a) and non-fatal MI, D: CumLp(a) and non-fatal stroke, E: CumLp(a) and unplanned RV, F: CumLp(a) and all-cause death. MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; RV, revascularization Kaplan-Meier survival curves for Lp(a) in relation to endpoint events. A: Lp(a) and MACCE, B: Lp(a) and CV death, C: Lp(a) and non-fatal MI, D: Lp(a) and non-fatal stroke, E: Lp(a) and unplanned RV, F: Lp(a) and all-cause death.Lp(a), lipoprotein(a); CumLp(a), cumulative lipoprotein(a); MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; RV, revascularization Kaplan-Meier survival curves for CumLp(a) in relation to endpoint events. A: CumLp(a) and MACCE, B: CumLp(a) and CV death, C: CumLp(a) and non-fatal MI, D: CumLp(a) and non-fatal stroke, E: CumLp(a) and unplanned RV, F: CumLp(a) and all-cause death. MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; RV, revascularization Multivariable associations of Lp(a) and CumLp(a) with endpoint events Table 2 summarized findings from Cox proportional hazards models assessing the relationship between Lp(a), CumLp(a), and endpoint outcomes across three analytic models. Across three models—model 1 (unadjusted), model 2 (adjusted for age and sex), and model 3 (further adjusted for age, sex, and variables with P < 0.05 in Table S1; detailed HRs and 95% CIs for all covariates were provided in Table S1 to enhance transparency and reproducibility)—patients in the highest Lp(a) quartile (Q4) showed higher risks of adverse events than those in Q1. For MACCE, the hazard ratios (HRs) were 2.151 (95% CI 1.790–2.584), 1.930 (1.605–2.321), and 1.652 (1.359–2.007) for models 1–3, respectively. Cardiovascular death presented HRs of 4.138 (2.868–5.969), 3.262 (2.259–4.711), and 2.157 (1.457–3.192). For non-fatal MI, the HRs were 3.527 (2.263–5.498), 3.357 (2.148–5.246), and 3.455 (2.186–5.460), while non-fatal stroke showed HRs of 2.170 (1.455–3.237), 1.832 (1.226–2.738), and 1.930 (1.291–2.886). In addition, each one-unit rise in Log10[Lp(a)] corresponded to increased risks: MACCE by 1.342, 1.103, and 0.658; cardiovascular death by 3.929, 3.063, and 1.506; non-fatal MI by 3.007, 3.007, and 2.627; and non-fatal stroke by 1.210, 0.872, and 0.917 (all P < 0.01).Table 2Multivariable Cox regression analysis of the correlation between Lp(a) and CumLp(a) with endpoint eventsModel 1Model 2Model 3HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueMACCE Lp(a): Q1RefRefRef Lp(a): Q20.777 (0.623, 0.968)0.0250.741 (0.595, 0.924)0.0080.783 (0.628, 0.977)0.031 Lp(a): Q31.282 (1.053, 1.561)0.0131.131 (0.928, 1.379)0.2231.062 (0.868, 1.300)0.559 Lp(a): Q42.151 (1.790, 2.584)< 0.0011.930 (1.605, 2.321)< 0.0011.652 (1.359, 2.007)< 0.001 P for trend< 0.001< 0.001< 0.001 Log10(Lp(a))2.342 (1.955, 2.805)< 0.0012.103 (1.752, 2.524)< 0.0011.658 (1.380, 1.991)< 0.001 CumLp(a): Q1RefRefRef CumLp(a): Q20.982 (0.786, 1.227)0.8750.896 (0.717, 1.121)0.3380.937 (0.749, 1.172)0.567 CumLp(a): Q31.466 (1.194, 1.800)< 0.0011.205 (0.976, 1.488)0.0821.146 (0.927, 1.417)0.208 CumLp(a): Q42.688 (2.222, 3.251)< 0.0012.056 (1.682, 2.513)< 0.0011.697 (1.376, 2.093)< 0.001 P for trend< 0.001< 0.001< 0.001 CumLp(a)1.019 (1.017, 1.022)< 0.0011.016 (1.013, 1.019)< 0.0011.013 (1.010, 1.016)< 0.001Cardiovascular death Lp(a): Q1RefRefRef Lp(a): Q20.956 (0.607, 1.506)0.8450.852 (0.541, 1.344)0.4920.845 (0.534, 1.337)0.472 Lp(a): Q32.598 (1.773, 3.807)< 0.0011.968 (1.341, 2.888)0.0011.413 (0.948, 2.107)0.089 Lp(a): Q44.138 (2.868, 5.969)< 0.0013.262 (2.259, 4.711)< 0.0012.157 (1.457, 3.192)< 0.001 P for trend< 0.001< 0.001< 0.001 Log10(Lp(a))4.929 (3.572, 6.802)< 0.0014.063 (2.915, 5.663)< 0.0012.506 (1.749, 3.591)< 0.001 CumLp(a): Q1RefRefRef CumLp(a): Q20.833 (0.510, 1.360)0.4650.662 (0.405, 1.083)0.1000.601 (0.366, 0.988)0.045 CumLp(a): Q32.606 (1.746, 3.889)< 0.0011.618 (1.077, 2.432)0.0201.130 (0.740, 1.725)0.573 CumLp(a): Q45.315 (3.649, 7.741)< 0.0012.765 (1.875, 4.078)< 0.0011.675 (1.106, 2.537)0.015 P for trend< 0.001< 0.001< 0.001 CumLp(a)1.025 (1.022, 1.029)< 0.0011.018 (1.015, 1.022)< 0.0011.014 (1.010, 1.019)< 0.001Non-fatal MI Lp(a): Q1RefRefRef Lp(a): Q20.968 (0.562, 1.669)0.9070.950 (0.551, 1.639)0.8551.145 (0.658, 1.991)0.632 Lp(a): Q31.282 (0.769, 2.137)0.3401.214 (0.726, 2.030)0.4591.394 (0.825, 2.354)0.214 Lp(a): Q43.527 (2.263, 5.498)< 0.0013.357 (2.148, 5.246)< 0.0013.455 (2.186, 5.460)< 0.001 P for trend< 0.001< 0.001< 0.001 Log10(Lp(a))4.007 (2.602, 6.169)< 0.0014.007 (2.602, 6.169)< 0.0013.627 (2.368, 5.555)< 0.001 CumLp(a): Q1RefRefRef CumLp(a): Q21.034 (0.599, 1.785)0.9031.034 (0.599, 1.785)0.9031.208 (0.690, 2.114)0.508 CumLp(a): Q31.323 (0.787, 2.225)0.2911.323 (0.787, 2.225)0.2911.436 (0.839, 2.457)0.187 CumLp(a): Q43.806 (2.425, 5.971)< 0.0013.806 (2.425, 5.971)< 0.0013.759 (2.330, 6.066)< 0.001 P for trend< 0.001< 0.001< 0.001 CumLp(a)1.021 (1.016, 1.026)< 0.0011.021 (1.016, 1.026)< 0.0011.019 (1.014, 1.024)< 0.001Non-fatal stroke Lp(a): Q1RefRefRef Lp(a): Q20.970 (0.613, 1.537)0.8980.895 (0.565, 1.418)0.6370.993 (0.625, 1.576)0.975 Lp(a): Q31.346 (0.877, 2.068)0.1741.108 (0.720, 1.706)0.6421.194 (0.775, 1.841)0.421 Lp(a): Q42.170 (1.455, 3.237)< 0.0011.832 (1.226, 2.738)0.0031.930 (1.291, 2.886)0.001 P for trend< 0.0010.0010.001 Log10(Lp(a))2.210 (1.516, 3.221)< 0.0011.872 (1.276, 2.747)0.0011.917 (1.316, 2.791)0.001 CumLp(a): Q1RefRefRef CumLp(a): Q21.280 (0.789, 2.076)0.3171.087 (0.669, 1.767)0.7371.145 (0.704, 1.861)0.586 CumLp(a): Q31.586 (0.995, 2.528)0.0531.136 (0.706, 1.828)0.5991.228 (0.764, 1.974)0.396 CumLp(a): Q43.143 (2.051, 4.815)< 0.0011.974 (1.264, 3.082)0.0032.032 (1.304, 3.167)0.002 P for trend< 0.0010.0010.001 CumLp(a)1.018 (1.013, 1.023)< 0.0011.012 (1.007, 1.018)< 0.0011.012 (1.007, 1.018)< 0.001Unplanned revascularization Lp(a): Q1RefRefRef Lp(a): Q20.681 (0.509, 0.911)0.0100.683 (0.511, 0.915)0.0100.726 (0.540, 0.976)0.034 Lp(a): Q30.863 (0.657, 1.135)0.2920.854 (0.648, 1.124)0.2610.861 (0.650, 1.142)0.299 Lp(a): Q41.039 (0.797, 1.354)0.7771.048 (0.802, 1.368)0.7320.943 (0.716, 1.241)0.675 P for trend0.0200.0180.169 Log10(Lp(a))1.098 (0.864, 1.395)0.4441.106 (0.868, 1.409)0.4141.033 (0.812, 1.313)0.794 CumLp(a): Q1RefRefRef CumLp(a): Q20.981 (0.737, 1.307)0.8980.976 (0.732, 1.301)0.8671.026 (0.766, 1.374)0.864 CumLp(a): Q31.074 (0.811, 1.422)0.6181.069 (0.800, 1.427)0.6531.058 (0.788, 1.420)0.707 CumLp(a): Q41.179 (0.892, 1.558)0.2461.174 (0.874, 1.578)0.8271.045 (0.772, 1.414)0.776 P for trend0.5490.5970.009 CumLp(a)1.005 (1.000, 1.010)0.0631.005 (1.000, 1.010)0.0631.003 (0.997, 1.008)0.343All-cause death Lp(a): Q1RefRefRef Lp(a): Q20.898 (0.673, 1.197)0.4620.774 (0.580, 1.033)0.0820.799 (0.598, 1.069)0.131 Lp(a): Q31.547 (1.196, 2.001)0.0011.104 (0.853, 1.431)0.4520.854 (0.652, 1.117)0.249 Lp(a): Q41.957 (1.524, 2.514)< 0.0011.477 (1.149, 1.899)0.0021.137 (0.871, 1.484)0.345 P for trend< 0.001< 0.0010.016 Log10(Lp(a))2.260 (1.788, 2.857)< 0.0011.722 (1.352, 2.194)< 0.0011.230 (0.943, 1.604)0.127 CumLp(a): Q1RefRefRef CumLp(a): Q21.151 (0.836, 1.584)0.3900.842 (0.611, 1.161)0.2940.817 (0.587, 1.138)0.231 CumLp(a): Q32.131 (1.596, 2.844)< 0.0011.143 (0.852, 1.533)0.3720.910 (0.665, 1.244)0.553 CumLp(a): Q43.330 (2.528, 4.385)< 0.0011.418 (1.068, 1.884)0.0160.972 (0.705, 1.340)0.862 CumLp(a)1.020 (1.016, 1.023)< 0.0011.010 (1.006, 1.013)< 0.0011.006 (1.002, 1.010)0.004Model 1: unadjustedModel 2: adjusted for age and sexModel 3: adjusted for age, sex, and variables with P < 0.05 in the univariate Cox regression analysis in Table S1 for MACCE, cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death, respectivelyLp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, Ref Reference, HR Hazard ratio, CI Confidence interval Table 2Multivariable Cox regression analysis of the correlation between Lp(a) and CumLp(a) with endpoint eventsModel 1Model 2Model 3HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueMACCE Lp(a): Q1RefRefRef Lp(a): Q20.777 (0.623, 0.968)0.0250.741 (0.595, 0.924)0.0080.783 (0.628, 0.977)0.031 Lp(a): Q31.282 (1.053, 1.561)0.0131.131 (0.928, 1.379)0.2231.062 (0.868, 1.300)0.559 Lp(a): Q42.151 (1.790, 2.584)< 0.0011.930 (1.605, 2.321)< 0.0011.652 (1.359, 2.007)< 0.001 P for trend< 0.001< 0.001< 0.001 Log10(Lp(a))2.342 (1.955, 2.805)< 0.0012.103 (1.752, 2.524)< 0.0011.658 (1.380, 1.991)< 0.001 CumLp(a): Q1RefRefRef CumLp(a): Q20.982 (0.786, 1.227)0.8750.896 (0.717, 1.121)0.3380.937 (0.749, 1.172)0.567 CumLp(a): Q31.466 (1.194, 1.800)< 0.0011.205 (0.976, 1.488)0.0821.146 (0.927, 1.417)0.208 CumLp(a): Q42.688 (2.222, 3.251)< 0.0012.056 (1.682, 2.513)< 0.0011.697 (1.376, 2.093)< 0.001 P for trend< 0.001< 0.001< 0.001 CumLp(a)1.019 (1.017, 1.022)< 0.0011.016 (1.013, 1.019)< 0.0011.013 (1.010, 1.016)< 0.001Cardiovascular death Lp(a): Q1RefRefRef Lp(a): Q20.956 (0.607, 1.506)0.8450.852 (0.541, 1.344)0.4920.845 (0.534, 1.337)0.472 Lp(a): Q32.598 (1.773, 3.807)< 0.0011.968 (1.341, 2.888)0.0011.413 (0.948, 2.107)0.089 Lp(a): Q44.138 (2.868, 5.969)< 0.0013.262 (2.259, 4.711)< 0.0012.157 (1.457, 3.192)< 0.001 P for trend< 0.001< 0.001< 0.001 Log10(Lp(a))4.929 (3.572, 6.802)< 0.0014.063 (2.915, 5.663)< 0.0012.506 (1.749, 3.591)< 0.001 CumLp(a): Q1RefRefRef CumLp(a): Q20.833 (0.510, 1.360)0.4650.662 (0.405, 1.083)0.1000.601 (0.366, 0.988)0.045 CumLp(a): Q32.606 (1.746, 3.889)< 0.0011.618 (1.077, 2.432)0.0201.130 (0.740, 1.725)0.573 CumLp(a): Q45.315 (3.649, 7.741)< 0.0012.765 (1.875, 4.078)< 0.0011.675 (1.106, 2.537)0.015 P for trend< 0.001< 0.001< 0.001 CumLp(a)1.025 (1.022, 1.029)< 0.0011.018 (1.015, 1.022)< 0.0011.014 (1.010, 1.019)< 0.001Non-fatal MI Lp(a): Q1RefRefRef Lp(a): Q20.968 (0.562, 1.669)0.9070.950 (0.551, 1.639)0.8551.145 (0.658, 1.991)0.632 Lp(a): Q31.282 (0.769, 2.137)0.3401.214 (0.726, 2.030)0.4591.394 (0.825, 2.354)0.214 Lp(a): Q43.527 (2.263, 5.498)< 0.0013.357 (2.148, 5.246)< 0.0013.455 (2.186, 5.460)< 0.001 P for trend< 0.001< 0.001< 0.001 Log10(Lp(a))4.007 (2.602, 6.169)< 0.0014.007 (2.602, 6.169)< 0.0013.627 (2.368, 5.555)< 0.001 CumLp(a): Q1RefRefRef CumLp(a): Q21.034 (0.599, 1.785)0.9031.034 (0.599, 1.785)0.9031.208 (0.690, 2.114)0.508 CumLp(a): Q31.323 (0.787, 2.225)0.2911.323 (0.787, 2.225)0.2911.436 (0.839, 2.457)0.187 CumLp(a): Q43.806 (2.425, 5.971)< 0.0013.806 (2.425, 5.971)< 0.0013.759 (2.330, 6.066)< 0.001 P for trend< 0.001< 0.001< 0.001 CumLp(a)1.021 (1.016, 1.026)< 0.0011.021 (1.016, 1.026)< 0.0011.019 (1.014, 1.024)< 0.001Non-fatal stroke Lp(a): Q1RefRefRef Lp(a): Q20.970 (0.613, 1.537)0.8980.895 (0.565, 1.418)0.6370.993 (0.625, 1.576)0.975 Lp(a): Q31.346 (0.877, 2.068)0.1741.108 (0.720, 1.706)0.6421.194 (0.775, 1.841)0.421 Lp(a): Q42.170 (1.455, 3.237)< 0.0011.832 (1.226, 2.738)0.0031.930 (1.291, 2.886)0.001 P for trend< 0.0010.0010.001 Log10(Lp(a))2.210 (1.516, 3.221)< 0.0011.872 (1.276, 2.747)0.0011.917 (1.316, 2.791)0.001 CumLp(a): Q1RefRefRef CumLp(a): Q21.280 (0.789, 2.076)0.3171.087 (0.669, 1.767)0.7371.145 (0.704, 1.861)0.586 CumLp(a): Q31.586 (0.995, 2.528)0.0531.136 (0.706, 1.828)0.5991.228 (0.764, 1.974)0.396 CumLp(a): Q43.143 (2.051, 4.815)< 0.0011.974 (1.264, 3.082)0.0032.032 (1.304, 3.167)0.002 P for trend< 0.0010.0010.001 CumLp(a)1.018 (1.013, 1.023)< 0.0011.012 (1.007, 1.018)< 0.0011.012 (1.007, 1.018)< 0.001Unplanned revascularization Lp(a): Q1RefRefRef Lp(a): Q20.681 (0.509, 0.911)0.0100.683 (0.511, 0.915)0.0100.726 (0.540, 0.976)0.034 Lp(a): Q30.863 (0.657, 1.135)0.2920.854 (0.648, 1.124)0.2610.861 (0.650, 1.142)0.299 Lp(a): Q41.039 (0.797, 1.354)0.7771.048 (0.802, 1.368)0.7320.943 (0.716, 1.241)0.675 P for trend0.0200.0180.169 Log10(Lp(a))1.098 (0.864, 1.395)0.4441.106 (0.868, 1.409)0.4141.033 (0.812, 1.313)0.794 CumLp(a): Q1RefRefRef CumLp(a): Q20.981 (0.737, 1.307)0.8980.976 (0.732, 1.301)0.8671.026 (0.766, 1.374)0.864 CumLp(a): Q31.074 (0.811, 1.422)0.6181.069 (0.800, 1.427)0.6531.058 (0.788, 1.420)0.707 CumLp(a): Q41.179 (0.892, 1.558)0.2461.174 (0.874, 1.578)0.8271.045 (0.772, 1.414)0.776 P for trend0.5490.5970.009 CumLp(a)1.005 (1.000, 1.010)0.0631.005 (1.000, 1.010)0.0631.003 (0.997, 1.008)0.343All-cause death Lp(a): Q1RefRefRef Lp(a): Q20.898 (0.673, 1.197)0.4620.774 (0.580, 1.033)0.0820.799 (0.598, 1.069)0.131 Lp(a): Q31.547 (1.196, 2.001)0.0011.104 (0.853, 1.431)0.4520.854 (0.652, 1.117)0.249 Lp(a): Q41.957 (1.524, 2.514)< 0.0011.477 (1.149, 1.899)0.0021.137 (0.871, 1.484)0.345 P for trend< 0.001< 0.0010.016 Log10(Lp(a))2.260 (1.788, 2.857)< 0.0011.722 (1.352, 2.194)< 0.0011.230 (0.943, 1.604)0.127 CumLp(a): Q1RefRefRef CumLp(a): Q21.151 (0.836, 1.584)0.3900.842 (0.611, 1.161)0.2940.817 (0.587, 1.138)0.231 CumLp(a): Q32.131 (1.596, 2.844)< 0.0011.143 (0.852, 1.533)0.3720.910 (0.665, 1.244)0.553 CumLp(a): Q43.330 (2.528, 4.385)< 0.0011.418 (1.068, 1.884)0.0160.972 (0.705, 1.340)0.862 CumLp(a)1.020 (1.016, 1.023)< 0.0011.010 (1.006, 1.013)< 0.0011.006 (1.002, 1.010)0.004Model 1: unadjustedModel 2: adjusted for age and sexModel 3: adjusted for age, sex, and variables with P < 0.05 in the univariate Cox regression analysis in Table S1 for MACCE, cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death, respectivelyLp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, Ref Reference, HR Hazard ratio, CI Confidence interval Multivariable Cox regression analysis of the correlation between Lp(a) and CumLp(a) with endpoint events Model 1: unadjusted Model 2: adjusted for age and sex Model 3: adjusted for age, sex, and variables with P < 0.05 in the univariate Cox regression analysis in Table S1 for MACCE, cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death, respectively Lp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, Ref Reference, HR Hazard ratio, CI Confidence interval For CumLp(a), participants in Q4 had higher risks of adverse outcomes than those in Q1 across all three models. The HRs for MACCE were 2.688 (95% CI 2.222–3.251), 2.056 (1.682–2.513), and 1.697 (1.376–2.093); for cardiovascular death, 5.315 (3.649–7.741), 2.765 (1.875–4.078), and 1.675 (1.106–2.537); for non-fatal MI, 3.806 (2.425–5.971), 3.806 (2.425–5.971), and 3.759 (2.330–6.066); and for non-fatal stroke, 3.143 (2.051–4.815), 1.974 (1.264–3.082), and 2.032 (1.304–3.167). Moreover, each one-unit rise in CumLp(a) was associated with stepwise increases in risk across the three models: MACCE by 1.9%, 1.6%, and 1.3%; cardiovascular death by 2.5%, 1.8%, and 1.4%; non-fatal MI by 2.1%, 2.1%, and 1.9%; and non-fatal stroke by 1.8%, 1.2%, and 1.2% (all P < 0.001). Subgroup analysis Subgroup analysis in Fig. 3 revealed that elevated levels of Lp(a) and CumLp(a) were consistently associated with a higher risk of adverse clinical outcomes across most subgroups, with statistically significant interactions observed in some cases. For MACCE, both Lp(a) and CumLp(a) demonstrated a uniform trend of increased risk across all subgroups, with particularly pronounced associations in patients with hypertension, diabetes, and hyperlipidemia. For instance, in these subgroups, the HRs ranged from 1.518 to 1.716 for Lp(a) (P < 0.01) and from 1.993 to 2.144 for CumLp(a) (P < 0.001). A statistically significant interaction was observed only in the hypertension subgroup under the CumLp(a) model (P for interaction = 0.008). Fig. 3Forest plots of subgroup analysis. HR (95% CI) was tested by using Q1 as the reference (Q4 vs. Q1). A (1): Lp(a) and MACCE; A (2): CumLp(a) and MACCE; B (1): Lp(a) and CV death; B (2): CumLp(a) and CV death; C (1): Lp(a) and non-fatal MI; C (2): CumLp(a) and non-fatal MI; D (1): Lp(a) and non-fatal stroke; D (2): CumLp(a) and non-fatal stroke Lp(a), lipoprotein(a); CumLp(a), cumulative lipoprotein(a); STEMI, ST-segment elevation myocardial infarction; CKD, chronic kidney disease; MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval Forest plots of subgroup analysis. HR (95% CI) was tested by using Q1 as the reference (Q4 vs. Q1). A (1): Lp(a) and MACCE; A (2): CumLp(a) and MACCE; B (1): Lp(a) and CV death; B (2): CumLp(a) and CV death; C (1): Lp(a) and non-fatal MI; C (2): CumLp(a) and non-fatal MI; D (1): Lp(a) and non-fatal stroke; D (2): CumLp(a) and non-fatal stroke Lp(a), lipoprotein(a); CumLp(a), cumulative lipoprotein(a); STEMI, ST-segment elevation myocardial infarction; CKD, chronic kidney disease; MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval Regarding cardiovascular death, elevated levels of both Lp(a) and CumLp(a) were significantly associated with increased risk in most subgroups. The associations were strongest in individuals aged 60 years or younger and in those with hypertension (Lp(a): HR = 3.759 and 3.201; CumLp(a): HR = 5.472 and 2.912, respectively), with significant interaction terms detected for age and hypertension (P < 0.05). In the case of non-fatal MI, Lp(a) and CumLp(a) showed strong and consistent associations across all subgroups (maximum HR up to 5.368, P < 0.001), and no significant interaction was detected. For non-fatal stroke, CumLp(a) significantly increased the risk in patients with hypertension and hyperlipidemia (HR = 2.074 and 4.233, respectively; P < 0.01). In contrast, Lp(a) was only significantly associated with stroke risk in the hypertension subgroup (HR = 2.191, P < 0.001), where a clear interaction was also identified (P for interaction < 0.001). With respect to unplanned revascularization, both Lp(a) and CumLp(a) were associated with increased risk across most subgroups, notably in those with hypertension, diabetes, or hyperlipidemia. The effect of CumLp(a) appeared especially pronounced (HR = 2.605–4.233, P < 0.01), although no significant subgroup interactions were observed. Finally, for all-cause death, elevated Lp(a) and CumLp(a) levels were significantly associated with increased risk, particularly in individuals with hyperlipidemia (Lp(a): HR = 2.885; CumLp(a): HR = 4.209) and in those without CKD. However, no significant interactions were detected across subgroups. Sensitivity analysis To assess the robustness of the primary findings, two sensitivity analyses were performed. First, after excluding patients with severely impaired renal function (eGFR < 30 ml/min/1.73 m2), the associations between elevated Lp(a) and CumLp(a) levels and adverse cardiovascular outcomes remained largely unchanged (Table S2). Both Lp(a) and CumLp(a) showed strong and graded associations with increased risk of non-fatal MI, and non-fatal stroke, cardiovascular death and MACCE across all three models. Notably, individuals in the highest quartile of Lp(a) had significantly greater risks of MACCE (HR = 1.668), cardiovascular death (HR = 2.635), non-fatal MI (HR = 3.500), and stroke (HR = 1.962), all with P-values < 0.001. Similarly, those in the top CumLp(a) quartile had consistently elevated risks, particularly for cardiovascular death (HR = 1.975) and non-fatal MI (HR = 4.119). In the second sensitivity analysis (Table 3), using a range of clinically and statistically defined cut-off points for Lp(a) and CumLp(a), a consistent pattern emerged: higher thresholds were associated with greater risk for MACCE, cardiovascular death, non-fatal MI, and stroke. For instance, Lp(a) levels > 500 mg/L and CumLp(a) > 20.72 g/L·years were strongly predictive of adverse outcomes, with HRs ranging from 1.7 to 2.8 across endpoints (all P < 0.001). These associations remained consistent in the overall population and among those with preserved renal function (eGFR ≥ 30 ml/min/1.73 m2). Table 3Sensitivity analysis: grouped by different cutoff points of Lp(a) and CumLp(a)Total populationeGFR ≥ 30 ml/min/1.73m2HR (95% CI)P valueHR (95% CI)P valueMACCE Lp(a) > 243 mg/La1.450 (1.256, 1.674)< 0.0011.471 (1.270, 1.704)< 0.001 > 300 mg/Lb1.583 (1.373, 1.824)< 0.0011.617 (1.404, 1.862)< 0.001 > 318 mg/Lc1.692 (1.476, 1.940)< 0.0011.704 (1.482, 1.960)< 0.001 > 500 mg/Ld1.868 (1.610, 2.169)< 0.0011.874 (1.609, 2.182)< 0.001 CumLp(a) > 15.35 g/L·yearse1.428 (1.229, 1.659)< 0.0011.443 (1.237, 1.684)< 0.001 > 20.72 g/L·yearsf1.625 (1.407, 1.878)< 0.0011.639 (1.412, 1.902)< 0.001Cardiovascular death Lp(a) > 243 mg/La1.915 (1.458, 2.517)< 0.0012.057 (1.536, 2.755)< 0.001 > 300 mg/Lb1.736 (1.359, 2.219)< 0.0011.698 (1.303, 2.213)< 0.001 > 318 mg/Lc1.798 (1.414, 2.286)< 0.0011.800 (1.389, 2.332)< 0.001 > 500 mg/Ld1.912 (1.511, 2.418)< 0.0011.995 (1.547, 2.572)< 0.001 CumLp(a) > 15.35 g/L·yearse1.866 (1.392, 2.501)< 0.0011.910 (1.395, 2.614)< 0.001 > 20.72 g/L·yearsf1.970 (1.518, 2.556)< 0.0012.011 (1.530, 2.644)< 0.001Non-fatal MI Lp(a) > 243 mg/La2.237 (1.605, 3.118)< 0.0012.337 (1.652, 3.307)< 0.001 > 300 mg/Lb2.463 (1.798, 3.373)< 0.0012.578 (1.858, 3.578)< 0.001 > 318 mg/Lc2.816 (2.057, 3.856)< 0.0012.983 (2.150, 4.140)< 0.001 > 500 mg/Ld2.635 (1.935, 3.587)< 0.0012.772 (2.016, 3.812)< 0.001 CumLp(a) > 15.35 g/L·yearse2.271 (1.626, 3.174)< 0.0012.441 (1.722, 3.460)< 0.001 > 20.72 g/L·yearsf2.618 (1.918, 3.576)< 0.0012.792 (2.020, 3.860)< 0.001Non-fatal stroke Lp(a) > 243 mg/La1.554 (1.164, 2.075)0.0031.602 (1.196, 2.145)0.002 > 300 mg/Lb1.878 (1.417, 2.487)< 0.0011.932 (1.453, 2.568)< 0.001 > 318 mg/Lc1.917 (1.450, 2.534)< 0.0011.964 (1.481, 2.606)< 0.001 > 500 mg/Ld1.958 (1.449, 2.645)< 0.0011.989 (1.465, 2.699)< 0.001 CumLp(a) > 15.35 g/L·yearse1.509 (1.116, 2.041)0.0071.567 (1.155, 2.125)0.004 > 20.72 g/L·yearsf1.706 (1.281, 2.271)< 0.0011.767 (1.323, 2.361)< 0.001Unplanned revascularization Lp(a) > 243 mg/La1.052 (0.857, 1.290)0.6281.033 (0.840, 1.270)0.761 > 300 mg/Lb1.048 (0.853, 1.288)0.6531.026 (0.833, 1.265)0.808 > 318 mg/Lc1.070 (0.870, 1.315)0.5231.057 (0.857, 1.303)0.603 > 500 mg/Ld1.090 (0.851, 1.396)0.4971.086 (0.843, 1.398)0.524 CumLp(a) > 15.35 g/L·yearse1.037 (0.839, 1.283)0.7351.023 (0.825, 1.268)0.838 > 20.72 g/L·yearsf1.050 (0.847, 1.301)0.6571.043 (0.839, 1.297)0.704All-cause death Lp(a) > 243 mg/La1.104 (0.901, 1.353)0.3401.189 (0.958, 1.476)0.116 > 300 mg/Lb1.111 (0.908, 1.359)0.3061.126 (0.908, 1.396)0.279 > 318 mg/Lc1.103 (0.905, 1.344)0.3301.110 (0.898, 1.373)0.336 > 500 mg/Ld1.428 (1.174, 1.737)< 0.0011.475 (1.191, 1.825)< 0.001 CumLp(a) > 15.35 g/L·yearse1.067 (0.860, 1.323)0.5571.095 (0.871, 1.376)0.438 > 20.72 g/L·yearsf1.096 (0.895, 1.343)0.3731.161 (0.937, 1.438)0.172For MACCE, cardiovascular death, nonfatal MI, nonfatal stroke, unplanned revascularization, and all-cause death, the multivariable adjusted models adjusted for age, sex, and variables with P < 0.05 in the univariate Cox regression analysis in Table S1eGFR estimated glomerular filtration rate, Lp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, HR Hazard ratio, CI Confidence intervala243 mg/L was the median of Lp(a), and Lp(a) ≤ 243 mg/L was used as the reference for testingb300 mg/L was the risk threshold of Lp(a) in the Chinese population, and Lp(a) ≤ 300 mg/L was used as the reference for testingc318 mg/L was the mean of Lp(a), and Lp(a) ≤ 318 mg/L was used as the reference for testingd500 mg/L was the risk threshold of Lp(a) in the European and American population, and Lp(a) ≤ 500 mg/L was used as the reference for testinge15.35 g/L·years was the median of CumLp(a), and CumLp(a) ≤ 15.35 g/L·years was used as the reference for testingf20.72 g/L·years was the mean of CumLp(a), and CumLp(a) ≤ 20.72 g/L·years was used as the reference for testing Table 3Sensitivity analysis: grouped by different cutoff points of Lp(a) and CumLp(a)Total populationeGFR ≥ 30 ml/min/1.73m2HR (95% CI)P valueHR (95% CI)P valueMACCE Lp(a) > 243 mg/La1.450 (1.256, 1.674)< 0.0011.471 (1.270, 1.704)< 0.001 > 300 mg/Lb1.583 (1.373, 1.824)< 0.0011.617 (1.404, 1.862)< 0.001 > 318 mg/Lc1.692 (1.476, 1.940)< 0.0011.704 (1.482, 1.960)< 0.001 > 500 mg/Ld1.868 (1.610, 2.169)< 0.0011.874 (1.609, 2.182)< 0.001 CumLp(a) > 15.35 g/L·yearse1.428 (1.229, 1.659)< 0.0011.443 (1.237, 1.684)< 0.001 > 20.72 g/L·yearsf1.625 (1.407, 1.878)< 0.0011.639 (1.412, 1.902)< 0.001Cardiovascular death Lp(a) > 243 mg/La1.915 (1.458, 2.517)< 0.0012.057 (1.536, 2.755)< 0.001 > 300 mg/Lb1.736 (1.359, 2.219)< 0.0011.698 (1.303, 2.213)< 0.001 > 318 mg/Lc1.798 (1.414, 2.286)< 0.0011.800 (1.389, 2.332)< 0.001 > 500 mg/Ld1.912 (1.511, 2.418)< 0.0011.995 (1.547, 2.572)< 0.001 CumLp(a) > 15.35 g/L·yearse1.866 (1.392, 2.501)< 0.0011.910 (1.395, 2.614)< 0.001 > 20.72 g/L·yearsf1.970 (1.518, 2.556)< 0.0012.011 (1.530, 2.644)< 0.001Non-fatal MI Lp(a) > 243 mg/La2.237 (1.605, 3.118)< 0.0012.337 (1.652, 3.307)< 0.001 > 300 mg/Lb2.463 (1.798, 3.373)< 0.0012.578 (1.858, 3.578)< 0.001 > 318 mg/Lc2.816 (2.057, 3.856)< 0.0012.983 (2.150, 4.140)< 0.001 > 500 mg/Ld2.635 (1.935, 3.587)< 0.0012.772 (2.016, 3.812)< 0.001 CumLp(a) > 15.35 g/L·yearse2.271 (1.626, 3.174)< 0.0012.441 (1.722, 3.460)< 0.001 > 20.72 g/L·yearsf2.618 (1.918, 3.576)< 0.0012.792 (2.020, 3.860)< 0.001Non-fatal stroke Lp(a) > 243 mg/La1.554 (1.164, 2.075)0.0031.602 (1.196, 2.145)0.002 > 300 mg/Lb1.878 (1.417, 2.487)< 0.0011.932 (1.453, 2.568)< 0.001 > 318 mg/Lc1.917 (1.450, 2.534)< 0.0011.964 (1.481, 2.606)< 0.001 > 500 mg/Ld1.958 (1.449, 2.645)< 0.0011.989 (1.465, 2.699)< 0.001 CumLp(a) > 15.35 g/L·yearse1.509 (1.116, 2.041)0.0071.567 (1.155, 2.125)0.004 > 20.72 g/L·yearsf1.706 (1.281, 2.271)< 0.0011.767 (1.323, 2.361)< 0.001Unplanned revascularization Lp(a) > 243 mg/La1.052 (0.857, 1.290)0.6281.033 (0.840, 1.270)0.761 > 300 mg/Lb1.048 (0.853, 1.288)0.6531.026 (0.833, 1.265)0.808 > 318 mg/Lc1.070 (0.870, 1.315)0.5231.057 (0.857, 1.303)0.603 > 500 mg/Ld1.090 (0.851, 1.396)0.4971.086 (0.843, 1.398)0.524 CumLp(a) > 15.35 g/L·yearse1.037 (0.839, 1.283)0.7351.023 (0.825, 1.268)0.838 > 20.72 g/L·yearsf1.050 (0.847, 1.301)0.6571.043 (0.839, 1.297)0.704All-cause death Lp(a) > 243 mg/La1.104 (0.901, 1.353)0.3401.189 (0.958, 1.476)0.116 > 300 mg/Lb1.111 (0.908, 1.359)0.3061.126 (0.908, 1.396)0.279 > 318 mg/Lc1.103 (0.905, 1.344)0.3301.110 (0.898, 1.373)0.336 > 500 mg/Ld1.428 (1.174, 1.737)< 0.0011.475 (1.191, 1.825)< 0.001 CumLp(a) > 15.35 g/L·yearse1.067 (0.860, 1.323)0.5571.095 (0.871, 1.376)0.438 > 20.72 g/L·yearsf1.096 (0.895, 1.343)0.3731.161 (0.937, 1.438)0.172For MACCE, cardiovascular death, nonfatal MI, nonfatal stroke, unplanned revascularization, and all-cause death, the multivariable adjusted models adjusted for age, sex, and variables with P < 0.05 in the univariate Cox regression analysis in Table S1eGFR estimated glomerular filtration rate, Lp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, HR Hazard ratio, CI Confidence intervala243 mg/L was the median of Lp(a), and Lp(a) ≤ 243 mg/L was used as the reference for testingb300 mg/L was the risk threshold of Lp(a) in the Chinese population, and Lp(a) ≤ 300 mg/L was used as the reference for testingc318 mg/L was the mean of Lp(a), and Lp(a) ≤ 318 mg/L was used as the reference for testingd500 mg/L was the risk threshold of Lp(a) in the European and American population, and Lp(a) ≤ 500 mg/L was used as the reference for testinge15.35 g/L·years was the median of CumLp(a), and CumLp(a) ≤ 15.35 g/L·years was used as the reference for testingf20.72 g/L·years was the mean of CumLp(a), and CumLp(a) ≤ 20.72 g/L·years was used as the reference for testing Sensitivity analysis: grouped by different cutoff points of Lp(a) and CumLp(a) For MACCE, cardiovascular death, nonfatal MI, nonfatal stroke, unplanned revascularization, and all-cause death, the multivariable adjusted models adjusted for age, sex, and variables with P < 0.05 in the univariate Cox regression analysis in Table S1 eGFR estimated glomerular filtration rate, Lp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, HR Hazard ratio, CI Confidence interval a243 mg/L was the median of Lp(a), and Lp(a) ≤ 243 mg/L was used as the reference for testing b300 mg/L was the risk threshold of Lp(a) in the Chinese population, and Lp(a) ≤ 300 mg/L was used as the reference for testing c318 mg/L was the mean of Lp(a), and Lp(a) ≤ 318 mg/L was used as the reference for testing d500 mg/L was the risk threshold of Lp(a) in the European and American population, and Lp(a) ≤ 500 mg/L was used as the reference for testing e15.35 g/L·years was the median of CumLp(a), and CumLp(a) ≤ 15.35 g/L·years was used as the reference for testing f20.72 g/L·years was the mean of CumLp(a), and CumLp(a) ≤ 20.72 g/L·years was used as the reference for testing RCS and threshold effects analysis After model adjustment, RCS analysis revealed that the risk of other individual adverse outcomes and MACCE, excluding unplanned revascularization, was nonlinearly associated with log10[Lp(a)]. For log10[CumLp(a)], a nonlinear trend was evident only for MACCE and other adverse outcomes (such as non-fatal MI and cardiovascular death) (P for nonlinearity < 0.05; Fig. 4). As reported in Table 4, the threshold-effect analysis indicated that when log10[Lp(a)] or log10[CumLp(a)] exceeded their respective cut-off values, the likelihood of these events rose significantly (P < 0.001). Fig. 4RCS plots of the relationship between Lp(a) and CumLp(a) with endpoint events. A (1): Log10(Lp(a)) and MACCE; A (2): Log10(CumLp(a)) and MACCE; B (1): Log10(Lp(a)) and CV death; B (2): Log10(CumLp(a)) and CV death; C (1): Log10(Lp(a)) and non-fatal MI; C (2): Log10(CumLp(a)) and non-fatal MI; D (1): Log10(Lp(a)) and non-fatal stroke; D (2): Log10(CumLp(a)) and non-fatal stroke; E (1): Log10(Lp(a)) and unplanned revascularization; E (2): Log10(CumLp(a)) and unplanned revascularization; F (1): Log10(Lp(a)) and all-cause death; F (2): Log10(CumLp(a)) and all-cause death; Lp(a), lipoprotein(a); CumLp(a), cumulative lipoprotein(a); MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; RV, revascularization; HR, hazard ratio; CI, confidence interval RCS plots of the relationship between Lp(a) and CumLp(a) with endpoint events. A (1): Log10(Lp(a)) and MACCE; A (2): Log10(CumLp(a)) and MACCE; B (1): Log10(Lp(a)) and CV death; B (2): Log10(CumLp(a)) and CV death; C (1): Log10(Lp(a)) and non-fatal MI; C (2): Log10(CumLp(a)) and non-fatal MI; D (1): Log10(Lp(a)) and non-fatal stroke; D (2): Log10(CumLp(a)) and non-fatal stroke; E (1): Log10(Lp(a)) and unplanned revascularization; E (2): Log10(CumLp(a)) and unplanned revascularization; F (1): Log10(Lp(a)) and all-cause death; F (2): Log10(CumLp(a)) and all-cause death; Lp(a), lipoprotein(a); CumLp(a), cumulative lipoprotein(a); MACCE, major adverse cardiac and cerebrovascular events; CV, cardiovascular; MI, myocardial infarction; RV, revascularization; HR, hazard ratio; CI, confidence interval Table 4Threshold effects analysis of Lp(a) and CumLp(a) on endpoint eventsMACCECardiovascular deathNon-fatal MINon-fatal strokeAll-cause deathHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueLog10 (Lp(a)) Single-segment regression model1.658 (1.380–1.991)< 0.0012.506 (1.749–3.591)< 0.0013.627 (2.368–5.555)< 0.0011.917 (1.316–2.791)0.0011.230 (0.943–1.604)0.127 Two-segment regression model Inflection point (K)2.3342.3122.2252.3502.605 < K0.802 (0.614–1.049)0.1070.866 (0.484–1.552)0.6300.787 (0.368–1.68)0.5350.912 (0.497–1.675)0.7670.927 (0.675–1.273)0.640 > K5.954 (4.424–8.013)< 0.0018.721 (5.538–13.733)< 0.00110.266 (5.827–18.084)< 0.0014.732 (2.491–8.991)< 0.0013.405 (1.762–6.581)< 0.001P for likelihood ratio test> 0.05> 0.05> 0.05> 0.05> 0.05Log 10 (CumLp(a)) Single-segment regression model1.763 (1.451–2.142)< 0.0012.490 (1.692–3.665)< 0.0013.387 (2.118–5.415)< 0.001 Two-segment regression model Inflection point (K)1.1641.0360.887 < K0.834 (0.627–1.109)0.2120.637 (0.324–1.249)0.1890.584 (0.235–1.455)0.248 > K6.942 (5.150–9.358)< 0.00112.970 (8.647–19.456)< 0.0018.097 (4.896–13.391)< 0.001P for likelihood ratio test> 0.05> 0.05> 0.05Log10(Lp(a)) and Log10(CumLp(a)) were used to fit nonlinear regression models and threshold effect analysis for non-normal distributions of Lp(a) and CumLp(a) through log10 transformationLp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, HR Hazard ratio, CI Confidence interval Table 4Threshold effects analysis of Lp(a) and CumLp(a) on endpoint eventsMACCECardiovascular deathNon-fatal MINon-fatal strokeAll-cause deathHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueLog10 (Lp(a)) Single-segment regression model1.658 (1.380–1.991)< 0.0012.506 (1.749–3.591)< 0.0013.627 (2.368–5.555)< 0.0011.917 (1.316–2.791)0.0011.230 (0.943–1.604)0.127 Two-segment regression model Inflection point (K)2.3342.3122.2252.3502.605 < K0.802 (0.614–1.049)0.1070.866 (0.484–1.552)0.6300.787 (0.368–1.68)0.5350.912 (0.497–1.675)0.7670.927 (0.675–1.273)0.640 > K5.954 (4.424–8.013)< 0.0018.721 (5.538–13.733)< 0.00110.266 (5.827–18.084)< 0.0014.732 (2.491–8.991)< 0.0013.405 (1.762–6.581)< 0.001P for likelihood ratio test> 0.05> 0.05> 0.05> 0.05> 0.05Log 10 (CumLp(a)) Single-segment regression model1.763 (1.451–2.142)< 0.0012.490 (1.692–3.665)< 0.0013.387 (2.118–5.415)< 0.001 Two-segment regression model Inflection point (K)1.1641.0360.887 < K0.834 (0.627–1.109)0.2120.637 (0.324–1.249)0.1890.584 (0.235–1.455)0.248 > K6.942 (5.150–9.358)< 0.00112.970 (8.647–19.456)< 0.0018.097 (4.896–13.391)< 0.001P for likelihood ratio test> 0.05> 0.05> 0.05Log10(Lp(a)) and Log10(CumLp(a)) were used to fit nonlinear regression models and threshold effect analysis for non-normal distributions of Lp(a) and CumLp(a) through log10 transformationLp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, HR Hazard ratio, CI Confidence interval Threshold effects analysis of Lp(a) and CumLp(a) on endpoint events Log10(Lp(a)) and Log10(CumLp(a)) were used to fit nonlinear regression models and threshold effect analysis for non-normal distributions of Lp(a) and CumLp(a) through log10 transformation Lp(a) Lipoprotein(a), CumLp(a) Cumulative lipoprotein(a), MACCE Major adverse cardiac and cerebrovascular events, MI Myocardial infarction, HR Hazard ratio, CI Confidence interval Discussion Based on data from this large, single-center cohort, analyses showed that both Lp(a) and CumLp(a) were independently linked to higher risks of MACCE and several individual adverse endpoints. Evidence from subgroup and sensitivity assessments further reinforced these findings. Additionally, analyses revealed that log10[Lp(a)] showed both nonlinear patterns and threshold effects with respect to the risk of other individual adverse outcomes and MACCE, excluding unplanned revascularization. Similar associations were observed for log10[CumLp(a)], but limited to non-fatal MI, cardiovascular death, and MACCE. These insights not only underscore the importance of Lp(a) in the prognostic assessment of AMI patients but also highlight the value of considering cumulative Lp(a) levels in refining risk stratification and informing therapeutic strategies. Current evidence underscores that Lp(a) levels in circulation are predominantly governed by genetic factors, with minimal influence from environmental elements, diet, exercise, or interventions such as cholesterol ester transfer protein inhibitors, which only induce minor variations [30]. Conversely, statins may elevate Lp(a) concentrations [31]. Given its relative stability, a single lifetime measurement of Lp(a) is advised for the general populace [32]. However, variations in circulating levels and reference ranges across different countries and ethnicities reflect population heterogeneity and testing method discrepancies, complicating Lp(a) research [33, 34]. For instance, prior studies report that approximately 20–30% of individuals exhibit Lp(a) levels >50 mg/dL, a threshold widely recognized as indicative of high cardiovascular risk [26, 30]. In our study, around 19% of patients also had Lp(a) >50 mg/dL, a finding that is generally consistent with this prevalence when considering ethnic and methodological differences. Furthermore, we included this cutoff in our sensitivity analyses and found a strong association between Lp(a) >50 mg/dL and increased risk of MACCE and other adverse outcomes, as shown in Table 3. These results support the predictive validity of this threshold in our cohort. As an example, Suwa and colleagues reported that Lp(a) concentrations were strongly associated with major adverse cardiovascular events (MACE) among statin-treated patients with CHD [35]. Similarly, a recent investigation reported a clear association between higher Lp(a) concentrations and the risk of recurrent MI and overall mortality, particularly among individuals without diabetes [36]. Evidence from several investigations indicates that Lp(a) also plays an important role in risk assessment for acute coronary syndrome (ACS). A study conducted in 2022 reported that higher Lp(a) concentrations were independently associated with an increased incidence of MACE, even after accounting for CKD [37]. In addition, two other analyses demonstrated that incorporating Lp(a) levels into the GRACE scoring system improves prognostic evaluation in ACS, allowing for more accurate risk stratification [38, 39]. In contrast, analyses by Gencer and co-workers as well as Xu and colleagues did not demonstrate a clear relationship between Lp(a) and MACCE [16, 17]. In a recently conducted 3-year cohort follow-up, Corpataux and colleagues, together with a single-center investigation from Korea focusing on MI patients, did not detect any clear association between Lp(a) concentrations and unfavorable outcomes [40, 41]. Besides, elevated Lp(a) concentrations, as evidenced by a recent systematic review and meta-analysis, were found to markedly increase the risk of cardiovascular as well as overall mortality [42]. In interpreting our findings, special attention should be given to certain demographic characteristics observed in the MACCE group. For instance, the MACCE group exhibited a higher proportion of women and a lower prevalence of smoking and alcohol use—an observation that may initially seem counterintuitive. However, this phenomenon can be explained by baseline population differences: female AMI patients in our cohort tended to be older, with more comorbidities such as hypertension, diabetes, and CKD, worse cardiac function, and more severe coronary lesions—all of which are well-established contributors to poor cardiovascular prognosis. On the other hand, smoking and alcohol use were more common among younger male patients who generally had fewer comorbidities and better cardiac profiles, and were more likely to receive invasive interventions and optimal secondary prevention therapies. These favorable factors may attenuate their risk despite the presence of lifestyle risk behaviors. Although smoking and alcohol use were less frequent in the MACCE group in this cohort, this should not be interpreted as indicating a protective effect. Instead, the result must be understood in the context of population characteristics, sample distribution, and multiple confounding factors. The harmful effects of smoking and alcohol consumption on cardiovascular health are well-established and supported by extensive evidence. Future research will aim to refine the classification and quantification of lifestyle factors (e.g., smoking pack-years, alcohol consumption frequency and volume) to better assess their true impact in different populations. Despite these findings, the research landscape remains fragmented with varied conclusions and lacks a comprehensive examination of cumulative Lp(a) exposure effect on cardiovascular events in patients with AMI. And in the Chinese cohort of patients with AMI, our longitudinal work also examined how Lp(a) concentrations and long-term (cumulative) exposure relate nonlinearly to multiple outcomes. Numerous studies have examined how Lp(a) is associated with cardiovascular events in both the general population and individuals with CHD, but the underlying mechanisms are still not fully understood. Literature suggests several potential pathways: Firstly, Lp(a) may accumulate on the vascular wall, acting as a primary transporter of oxidized phospholipids, thus fostering atherosclerosis through endothelial injury, proliferation of smooth muscle cells, foam-cell development, and inflammatory activity within plaques [43–45]. Secondly, owing to its similarity to plasminogen activator inhibitor-1 and an inactive protease site, Lp(a) can impede fibrinolysis and create a prothrombotic milieu, elevating the risk of AMI and stroke through fibrinogen binding and harming cardiovascular health [43, 46]. Thirdly, Lp(a) is linked to increased valve calcification, progression, replacement rates, and coronary artery calcification, potentially exacerbating AMI prognosis by promoting osteogenic differentiation in valve interstitial cells via oxidized phospholipids [47]. Lastly, high Lp(a) levels may perpetuate an inflammatory and oxidative stress state, contributing to atherosclerosis progression and increasing the risk of recurrent cardiovascular events [48, 49]. Despite yielding significant insights, this study faces several limitations. Firstly, its observational nature and data constraints prevent establishing a causal link between Lp(a) and CumLp(a) levels and adverse outcomes in AMI patients. Secondly, while it accounted for numerous confounders, unaddressed variables such as psychological, social, and genetic factors, alongside unknown confounders, may still influence the results. Thirdly, since the main focus of this study was to investigate the association between Lp(a) levels and long-term cardiovascular outcomes, we primarily included traditional cardiovascular risk factors in the baseline characteristics. Myocardial necrosis biomarkers such as troponin and Creatine Kinase-MB were not listed in Table 1 because they mainly serve as diagnostic and severity indicators during the acute phase of MI rather than as stable predictors of long-term prognosis. Additionally, their values fluctuate significantly depending on the timing of sampling and treatment, which may introduce confounding bias if compared at baseline. Fourthly, the distribution of Lp(a) quartiles observed in our study may appear inconsistent with some prior epidemiological reports, largely due to ethnic differences, population characteristics, and assay heterogeneity. Asian populations, including Chinese individuals, generally have lower Lp(a) concentrations than Western populations, resulting in different quartile thresholds. Furthermore, we used an immunoturbidimetric assay—a method widely accepted and utilized in clinical laboratories in China. However, variability in calibration standards, detection platforms, and reporting units (e.g., mg/dL vs. nmol/L) across studies may result in discrepancies in absolute values. These factors limit direct comparisons of Lp(a) levels across studies but do not affect the validity of relative risk estimates, such as hazard ratios, which remain interpretable within the context of each specific population and assay methodology. Moreover, given these methodological and population-based variations, the findings should be interpreted primarily as reflecting associations rather than precise quantitative risk estimates, and caution is warranted when extrapolating absolute risk across different populations or laboratory settings. Fifthly, the exclusive inclusion of patients from a single center in China restricts the applicability of the findings, underscoring the need for validation across diverse populations and settings to enhance generalizability. In addition, Lp(a) concentrations were reported in mg/L, which is the standard reporting unit in most clinical laboratories in China, including our institution. Although this differs from the mg/dL or nmol/L units commonly used in international studies, the results can be easily interpreted using the conversion factor (1 mg/L = 0.1 mg/dL). For analyses treating Lp(a) as a continuous variable, this conversion indicates that each 0.1 mg/dL increase corresponds to a 1 mg/L increment in our dataset, while for categorical analyses, such as quartile grouping, the unit difference does not affect interpretation or comparability of the findings. Lastly, the study did not examine whether shifts in Lp(a) over time influence cardiovascular prognosis in patients with AMI, suggesting the need for further studies to clarify this issue. Conclusions Analysis of this cohort indicated that raised Lp(a) and CumLp(a) were independent predictors of unfavorable outcomes in patients with AMI. These observations imply that focusing on early recognition and control of increased Lp(a) levels in vulnerable groups, together with designing personalized therapeutic plans, may contribute to fewer cardiovascular events. Supplementary Information Supplementary Material 1. Supplementary Material 1.